Skip to main content

Nexlizet Disease Interactions

There are 5 disease interactions with Nexlizet (bempedoic acid/ezetimibe).

Major

Ezetimibe (applies to Nexlizet) liver disease

Major Potential Hazard, High plausibility.

Ezetimibe is not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to the unknown effects of increased exposure in this population.

Switch to professional interaction data

Moderate

Bempedoic acid (applies to Nexlizet) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Bempedoic acid has not been studied in patients with severe hepatic impairment (Child-Pugh C), therefore, caution is advised if used in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh A or B).

Switch to professional interaction data

Moderate

Bempedoic acid (applies to Nexlizet) hyperuricemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gout

Bempedoic acid can elevate serum uric acid. Caution is advised in patients with a history of gout. Assess uric acid levels periodically and monitor any signs or symptoms of hyperuricemia.

Switch to professional interaction data

Moderate

Bempedoic acid (applies to Nexlizet) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

There is limited experience with the use of bempedoic acid in patients with severe renal impairment, and the drug has not been studied in patients with end-stage renal disease (ESRD) receiving dialysis. Caution is advised if used in these patients.

Switch to professional interaction data

Moderate

Bempedoic acid (applies to Nexlizet) tendon injuries

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tendonitis, Renal Dysfunction

Bempedoic acid has been associated with an increased risk of tendon rupture or injury. Ruptures involving the rotator cuff, biceps, or Achilles tendon have been reported. Risk increases in patients over 60, those on corticosteroid or fluoroquinolone treatment, patients with renal failure, and patients with previous tendon disorders. Consider an alternative therapy in patients with a history of tendon disorders or rupture. Discontinue treatment if rupture of a tendon occurs or consider discontinuation if the patient experiences joint pain, swelling, or inflammation.

Switch to professional interaction data

Nexlizet drug interactions

There are 109 drug interactions with Nexlizet (bempedoic acid/ezetimibe).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer